Delcath Systems Reports Strong Q2 2026 Revenue Growth on HEPZATO Demand
Event summary
- Delcath Systems reported Q2 2026 revenue of $29.1 million, up from $24.2 million in Q2 2025.
- HEPZATO KIT revenue grew to $27.1 million, a 20% increase year-over-year.
- Gross margins improved to 90%, up from 86% in the prior-year quarter.
- The company has 31 active treatment centers and saw a 30% growth in HEPZATO volume.
The big picture
Delcath Systems is capitalizing on growing demand for its HEPZATO KIT, particularly in treating metastatic liver cancers. The company's focus on expanding treatment centers and physician adoption aligns with broader trends in interventional oncology, where targeted therapies are gaining traction. With strong cash reserves and no debt, Delcath appears well-positioned to scale its operations, though it must navigate increasing operational costs.
What we're watching
- Revenue Growth
- Whether Delcath can sustain its HEPZATO revenue growth through expanded treatment centers and physician adoption.
- Clinical Trials
- The pace at which Phase 2 trials for HEPZATO in combination therapies will yield results, particularly in metastatic breast cancer.
- Operational Efficiency
- How Delcath manages rising R&D and SG&A expenses while maintaining strong gross margins.
Related topics